Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CAVATAK + Pembrolizumab in Advanced NSCLC
NCT02824965Phase 1Unknown
- Sponsor
- Olivia Newton-John Cancer Research Institute
- Start
- Aug 2017
- Primary completion
- Jul 2021
- Modality
- Oncolytic Viruses, Microbiome Therapeutics
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of coxsackievirus a21 in non-small cell lung cancer (NSCLC), sponsored by Olivia Newton-John Cancer Research Institute. Primary endpoint: Incidence of Treatment-Emergent Adverse Events. Status: unknown.
02
Drugs
coxsackievirus a21
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT02824965.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02824965.